Abstract:<p>PDF file - 2002KB, Figure S1. Expression of CBP protein in benign and malignant human prostate tissues. Figure S2. Evaluation of expression of CBP protein in human PIN lesions. Figure S3 Generation of prostate-specific Cbp and Cbp/Pten deletion mice. Figure S4. Immunofluorescent cytochemistry and histological analysis of prostates in Cbp knockout and control mice. Figure S5. Effect of CBP and PTEN knockdown on expression of cell cycle-regulatory genes and the levels of H3K27Ac and H3K27me3 in LAPC-4 PCa cells. Figure S6. IHC analysis of DAB2IP, p27KIP1 and EZH2 protein in DU145 cells. Figure S7. Quantitative data of immunohistochemical results in prostate sections of Cbp/Pten deficient and 'wild-type' mice. Figure S8. Binding of EZH2 at DAB2IP, p27KIP1 and p21CIP1 loci in DU145 cells. Figure S9. Effect of CBP and PTEN deficiency on H3K27Ac and H3K27me3 levels at DAB2IP, p27KIP1 and p21CIP1 gene loci. Figure S10. Quantitative data of immunohistochemical results of proteins examined in Figure 6 in prostate sections of 6-month-old CbpL/L;PtenL/+ and Cbppc-/-;Ptenpc+/- mice Figure S11. The effect of panobinostat (LBH589) on H3K27Ac and H3K27me3 levels at the p21CIP1 locus and expression of phosphorylated AKT (AKT-p) and PHLPP1 in DU145 cells and quantification of IHC for Akt-p, H3K27Ac, H3K27me3, Ki-67 and TUNEL in mouse prostate tissues. Figure S12. Effects of LBH589 on apoptotic signaling pathways in prostate cancer cells in vitro and in vivo.</p>

Supplementary Table 1 from CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Supplementary Table 2 from CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Supplementary Figures 1-2, Tables 1-8 from Distinct Genomic Alterations in Prostate Cancers in Chinese and Western Populations Suggest Alternative Pathways of Prostate Carcinogenesis

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figures 1 - 12 from CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 1 from P300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 1 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Data from CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Table 1 from Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis

Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15Q24-25.1

Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplemental Table 1 from RB Loss Promotes Prostate Cancer Metastasis

Supplementary Table 2 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Supplementary Table 3 from Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis